Laboratory Corporation of America Holdings

Diadexus, Inc.

Gundo Diedrich

Michael R Bates

Gordon Parry

Jeff Sperinde

Ali Mukherjee

Stephen J Williams

Jennifer W Cook

Laurie Goodman

Jackie Papkoff

Shu-Hui Liu

Agnes Nowakowski

Mojgan Haddad

John William Winslow

Gerald J Wallweber

Xueguang Jin

Paul Levi Miller

Weidong Huang

Jodi Weidler

Astrid Strelow

Stephen John Williams

The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.

Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients

The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.

Methods of determining patient response by measurement of HER-3

The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex and the presence and/or amount of p95 in a sample. The invention also provides antibodies specific for Her-3.

Methods of determining patient response by measurement of HER-3 and P95

HER-3 antibodies and methods of use

Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.

Ovr110 antibody compositions and methods of use

OVR110 antibody compositions and methods of use

The invention provides isolated anti-Pro115 antibodies that bind to Pro115. The invention also encompasses compositions comprising an anti-Pro115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro115 antibodies. The invention encompasses a method of producing the anti-Pro115 antibodies. Other aspects of the invention are a method of killing an Pro115-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro115 antibody and a method of alleviating or treating an Pro115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro115 antibody to the mammal.

PRO115 antibody compositions and methods of use

Methods of determining patient response by measurement of Her-3

Growing community of inventors

South San Francisco, CA, United States of America

Gundo Diedrich